Jochem van Werkum

Showing 1-5 of 5 articles

Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay

Heestermans A, de Boer M, van Werkum J, Mosterd A, Gosselink A, Dambrink J, van Houwelingen K, Koopmans P, Hamm C, Zijlstra F, ten Berg J, van’t Hof A

August 30, 2011 | 10.4244/EIJV7I4A73

Triggering mechanisms of stent thrombosis

Zwart B, van Werkum J, Heestermans A, Kelder J, Zomer A, van’t Hof A, Verheugt F, ten Berg J

January 20, 2011

Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the On-Time 2 trial

Timmer J, ten Berg J, Heestermans A, Dill T, van Werkum J, Dambrink J, Suryapranata H, Ottervanger J, Hamm C, van’t Hof A

August 15, 2010

Platelet reactivity as a risk-factor for stent thrombosis: can this be one of the currently available appropriate methods to determine platelet reactivity?

van Werkum J, ten Berg J

August 20, 2008

Point-of-care platelet function testing in patients undergoing PCI: is it ready for use in clinical practice?

ten Berg J, van Werkum J

August 20, 2008

1

Latest news

Ischaemia with non-obstructive coronary arteries, OCT vs IVUS guidance in PCI; the ILUMIEN III and ILUMIEN IV trials…

January 20, 2021

The Year in Review

M. Lunardi et al

January 22, 2021

Elective Cardiac Invasive Procedures during the COVID-19 Outbreak

A. Chieffo et al.

January 8, 2021

Smoke signals – do they help to predict TAVI-associated stroke risk?

R. Kharbanda et al.

January 25, 2021

SCOPE 2, BASKET-SMALL 2 3 years, ALPHEUS, COMPARE-ABSORB, DUBIUS

(Thanks to the support of Biotronik)

January 13, 2021

Guidance Papers

Guidelines, consensus & position papers

August 28, 2020

This Week's JAA's: Redo-TAVI, Major bleeding in the Amulet Observational Study, OCT findings in ESR...

January 26, 2021

Valvular disease